ICG R15对肝细胞癌患者接受立体定向放射治疗发生放射性肝损伤的预测价值

肝脏 ›› 2018, Vol. 23 ›› Issue (11): 973-976.

ICG R15对肝细胞癌患者接受立体定向放射治疗发生放射性肝损伤的预测价值

孙静, 刘丽英, 杨晓, 张爱民, 张弢, 王佳, 张丹, 丁俊强, 李文刚, 段学章

100039 北京解放军第三○二医院肿瘤放射治疗中心

收稿日期:2018-06-11 发布日期:2020-04-28
通讯作者: 段学章,Email:duanxuezhang2006@163.com
基金资助:
首都特色基金(Z171100001017181)

ICG R15 in the Prediction of the radiation-induced liver damage of stereotactic body radiotherapy in patients with hepato cellular carcinoma

SUN Jing, LIU Li-ying, YANG Xiao, ZHANG Ai-min, ZHANG Tao, WANG Jia, ZHANG Dan, DING Jun-qiang, LI Wen-gang, DUAN Xue-zhang

Radiation Oncology Center, 302 Military Hospital of China, Beijing 100039, China

Received:2018-06-11 Published:2020-04-28
Contact: DUAN Xue-zhang, Email: duanxuezhang2006@163.com

摘要/Abstract

摘要： 目的分析吲哚菁绿15分钟清除率(ICG R15)对原发性肝细胞癌(HCC)患者接受立体定向放射治疗(SBRT)发生放射性肝损伤(RILD)的预测价值。方法前瞻性分析2016年10月1日至2017年8月31日行SBRT的HCC患者150例,治疗前1周内测量ICG R15值,SBRT治疗后随访至少1年。根据实验室检查结果判定是否发生RILD,分析放疗前ICG R15与RILD发生的相关性。结果 14例患者发生典型RILD,1例患者发生了不典型RILD。Child-Pugh B级患者的ICG R15值为(34.275±16.544)%,明显高于Child-Pugh A级患者值(8.936±11.134)%。通过ROC曲线确定ICG R15截断值(对应敏感度和特异度分别为0.667和0.778)为11.3%。ICG R15＜11.3%发生RILD的患者5例,ICG R15≥11.3%发生RILD患者10例(P=0.001)。多因素分析表明,放疗前ICG R15对预测RILD有意义,ICG R15≥11.3%组的相对危险度(RR)9.578, 95%可信区间 2.278~40.264 (P=0.002)。结论放疗前ICG R15是SBRT治疗HCC患者发生RILD的有效预测因素。

关键词: 原发性肝癌, 吲哚菁绿15分钟清除率, 放射性肝损伤, 立体定向放射治疗

Abstract: Objective To analyze the prediction value of indocyanine green 15-minute clearance rate (ICG R15) for radiation-induced liver damage (RILD) in patients with primary hepatocellular carcinoma (HCC) undergoing stereotactic body radiotherapy (SBRT). Methods From October 1st, 2016 to August 31st, 2017, 150 patients with HCC employing SBRT were enrolled in this prospective study. The ICG R15 values were measured 1 week before treatment, and biochemical parameters were measured at least 1 year after SBRT. RILD was diagnosed according to the published criteria. The relationship between the ICG R15 and RILD were analyzed in these 150 patients. Results Typical RILD occurred in 14 patients (93.3%), and atypical RILD occurred in 1 patient (6.7%). ICG R15 in Child-Pugh B patients (34.275±16.544%) was significantly higher than that in Child-Pugh A patients (8.936±11.134 %). ICG R15 cut-off value was defined as 11.3% by the receiver operating characteristic curve, whose corresponding sensitivity and specificity were 0.667 and 0.778, respectively. RILD occurred in 5 patients when ICG R15 was less than 11.3% and 10 patients when ICG R15 was more than 11.3% (P=0.001). Multivariate analysis showed that only ICG R15 before radiotherapy showed statistical significance in predicting RILD (RR 9.578, 95%CI: 2.278~40.264). Conclusion ICG R15 value is an effective predictor of RILD in patients with HCC after SBRT.

Key words: Primary hepatocellular carcinoma, Indocyanine green 15 min clearance rate, Radiation-induced liver damage, Stereotactic body radiotherapy

孙静, 刘丽英, 杨晓, 张爱民, 张弢, 王佳, 张丹, 丁俊强, 李文刚, 段学章. ICG R15对肝细胞癌患者接受立体定向放射治疗发生放射性肝损伤的预测价值[J]. 肝脏, 2018, 23(11): 973-976.

SUN Jing, LIU Li-ying, YANG Xiao, ZHANG Ai-min, ZHANG Tao, WANG Jia, ZHANG Dan, DING Jun-qiang, LI Wen-gang, DUAN Xue-zhang. ICG R15 in the Prediction of the radiation-induced liver damage of stereotactic body radiotherapy in patients with hepato cellular carcinoma[J]. Chinese Hepatolgy, 2018, 23(11): 973-976.

参考文献

[1] Hawkins MA, Dawson LA. Radiation therapy for hepatocellular carcinoma: from palliation to cure. Soc, 2011, 21:271-277.
[2] Han KH. Local radiotherapy for unresectable hepatocellular carcinoma patients who failed with transcatheter arterial chemoembolization: Int J Radiat Oncol, 2000, 47:1331-1335.
[3] Anscher MS. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol, 1995, 31:1237.
[4] Pan CC, Kavanagh BD, Dawson LA, et al. Radiation-associated liver injury. Int. J. Radiat. Oncol. Biol. Phys,2010, 76: S94-100.
[5] Yoon HI, Koom WS, Lee IJ, et al. The significance of ICG-R15 in predicting hepatic toxicity in patients receiving radiotherapy for hepatocellular carcinoma. Liver Int, 2012, 32:1165-1171.
[6] Bosch J, Abraldes JG, Berzigotti A, et al. Portal hypertension and gastrointestinal bleeding. Semin Liver Dis, 2008, 28:003-025.
[7] Benedict SH, Yenice KM, Followill D, et al. Stereotactic body radiation therapy: The report of AAPM Task Group 101. Med Phys, 2010, 37:4078-4101.
[8] Chandan Guha, Brian D. Kavanagh. Hepatic Radiation Toxicity: Avoidance and Amelioration. Oncol, 2011, 21:256-263.
[9] Gençel O, Naziroglu M, Celik O, et al. Selenium and vitamin E modulates radiation-induced liver toxicity in pregnant and nonpregnant rat: effects of colemanite and hematite shielding. Biol Trace Elem Res, 2010, 135:253-263.
[10] Laura A. Dawson, Daniel Normolle, James M. Balter, et al. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys, 2002, 53:810-821.
[11] Benson R, Madan R, Kilambi R, et al. Radiation induced liver disease: A clinical update. J Egypt Natl Canc Inst, 2016, 28:7-11.
[12] Scheingraber S, Richter S, Igna D, et al. Indocyanine green disappearance rate is the most useful marker for liver resection. Hepatogastroenterology, 2008, 55:1394.
[13] Lee CF, Yu MC, Kuo LM, et al. Using indocyanine green test to avoid post-hepatectomy liver dysfunction. Chang Gung Med J, 2007, 30:333.

[1]	孙亮, 周旋, 刘桂治, 林茂锐, 李明友, 曹东林. 肝癌患者肠道微生态结构变化的特点分析[J]. 肝脏, 2020, 25(3): 267-269.
[2]	王雨, 许达峰, 周开伦, 武金才, 丁驿超, 古海强, 谢明微, 林明花. TLR4和肠道菌群在原发性肝癌进展中动态变化及与预后的关系[J]. 肝脏, 2020, 25(3): 273-276.
[3]	周友乾, 罗心晨, 邹喜荣, 李翠, 欧阳帆, 尹凤鸣. HBsAg阴性HBV相关原发性肝癌临床特点分析[J]. 肝脏, 2020, 25(3): 288-291.
[4]	余守江, 王国兴, 马兰芳. TACE联合微波消融对原发性肝癌患者肿瘤组织灌注、免疫功能及预后的影响[J]. 肝脏, 2020, 25(3): 294-296.
[5]	李彦伟. PCR检测HBV前C/C基因启动子区变异与肝细胞癌的关系[J]. 肝脏, 2020, 25(3): 300-301.
[6]	沈张平, 王钦君, 季沈杰. 血清miR127-3P与原发性肝癌的相关性研究[J]. 肝脏, 2020, 25(3): 302-305.
[7]	王家欢, 李震. 对比经皮射频消融术和经腹腔镜下肝切除术治疗Ⅰa期原发性肝癌的临床效果[J]. 肝脏, 2020, 25(2): 146-148.
[8]	孙艳华, 夏瑞雪, 王宁, 鲍越. AFP-L3、AFP、GP73、ALP联合检测对原发性肝癌的诊断价值研究[J]. 肝脏, 2020, 25(1): 63-65.
[9]	张黎, 杨荣, 赵云. 原发性肝癌中血清PTN和GP73的表达及其在临床诊断中的意义[J]. 肝脏, 2020, 25(1): 56-58.
[10]	王恒, 蔡庆和, 涂华, 张林菲, 封彦青, 周华东. 前入路肝切除术在原发性肝癌手术中的应用价值分析[J]. 肝脏, 2019, 24(9): 1021-1024.
[11]	鲁斌, 黄晓宇, 夏秀梅, 陶进勇. 含奥沙利铂化疗方案联合DC-CIK细胞治疗原发性肝癌的临床疗效[J]. 肝脏, 2019, 24(7): 792-795.
[12]	赵鹏伟, 黄建钊, 柳严, 张佳伟, 刘延, 刘江伟. 原发性肝癌患者术后3年生存率与FHIT基因表达的关系[J]. 肝脏, 2019, 24(6): 661-664.
[13]	张洪川, 张玉玺, 段丛迪. 骨桥蛋白和Ezrin蛋白在原发性肝癌组织中的表达及其与临床特征和预后的相关性[J]. 肝脏, 2019, 24(5): 549-522.
[14]	陈林林, 王花花, 王娅菲, 樊慧, 赵乃阔, 胡庆军, 张正安. TACE联合索拉非尼对原发性肝癌的疗效及其预后相关影响因素[J]. 肝脏, 2019, 24(5): 571-573.
[15]	陈庆录, 张冠平. TACE联合索拉非尼治疗肝癌合并门静脉癌栓的临床疗效及安全性[J]. 肝脏, 2019, 24(5): 573-576.